Indivior Pharmaceuticals Inc.

Contributing Author

Recent Articles by Indivior Pharmaceuticals Inc.

Apr-16	Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse INDV GlobeNewswire
Apr-09	Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th INDV GlobeNewswire
Mar-31	New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities INDV +5.91% GlobeNewswire
Mar-17	National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder INDV GlobeNewswire
Mar-12	Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering INDV GlobeNewswire
Mar-12	Indivior Announces Proposed Convertible Senior Notes Offering INDV -6.00% GlobeNewswire
Mar-11	New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder INDV GlobeNewswire
Feb-26	Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results INDV GlobeNewswire
Feb-24	Indivior to Participate in Upcoming Investor Conferences INDV GlobeNewswire
Jan-28	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ INDV GlobeNewswire
Jan-26	Indivior Announces Completion of Redomiciliation to the United States INDV GlobeNewswire